Concerted perturbation observed in a hub network in Alzheimer's disease

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Liang, Dapeng ^a,b   Han, Guangchun ^a,b   Feng, Xuemei ^a   Sun, Jiya ^a,b   Duan, Yong ^c   Lei, Hongxing ^a,c  

^a Chinese Academy of Sciences   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c University of California Davis   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTATION; ALZHEIMER DISEASE; ARTICLE; BRAIN NERVE CELL; BRAIN REGION; CELL ACTIVITY; CELL SURVIVAL; DISEASE SEVERITY; GENE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ALGORITHM; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUB GENE; HUMAN; INTRACELLULAR SIGNALING; MICROENVIRONMENT; NERVE CELL NETWORK; PROTEIN INTERACTION; SIGNAL NOISE RATIO; SYNAPTIC TRANSMISSION;

AGING; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; BRAIN; DISEASE PROGRESSION; DRUG DISCOVERY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; NERVE NET; NEUROFIBRILLARY TANGLES; PLAQUE, AMYLOID; TRANSCRIPTOME;

EID: 84863994278     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040498     Document Type: Article

References (148)

1. Lei H, (2010) Amyloid and Alzheimer's disease. Protein & Cell 1: 312-314.
2. Lei H, Wu C, Wang Z, Duan Y, (2006) Molecular Dynamics Simulations and Free Energy Analyses on the Dimer Formation of an Amyloidogenic Heptapeptide from Human β2-Microglobulin: Implication for the Protofibril Structure. Journal of Molecular Biology 356: 1049-1063.
3. Klein WL, Krafft GA, Finch CE, (2001) Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci 24: 219-224.
4. Chiti F, Dobson CM, (2006) Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 75: 333-366.
5. Liang WS, Dunckley T, Beach TG, Grover A, Mastroeni D, et al. (2008) Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set. Physiological Genomics 33: 240-256.
6. Hock C, Heese K, Hulette C, Rosenberg C, Otten U, (2000) Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch Neurol 57: 846-851.
7. Loring JF, Wen X, Lee JM, Seilhamer J, Somogyi R, (2001) A gene expression profile of Alzheimer's disease. DNA Cell Biol 20: 683-695.
8. Blalock EM, (2004) Incipient Alzheimer's disease: Microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proceedings of the National Academy of Sciences 101: 2173-2178.
9. Dunckley T, Beach TG, Ramsey KE, Grover A, Mastroeni D, et al. (2006) Gene expression correlates of neurofibrillary tangles in Alzheimer's disease. Neurobiol Aging 27: 1359-1371.
10. Nunez-Iglesias J, Liu CC, Morgan TE, Finch CE, Zhou XJ, (2010) Joint genome-wide profiling of miRNA and mRNA expression in Alzheimer's disease cortex reveals altered miRNA regulation. PLoS ONE 5: e8898.
11. Gendelman HE, Williams C, Mehrian Shai R, Wu Y, Hsu Y-H, et al. (2009) Transcriptome Analysis of Synaptoneurosomes Identifies Neuroplasticity Genes Overexpressed in Incipient Alzheimer's Disease. PLoS ONE 4: e4936.
12. Maes OC, Xu S, Yu B, Chertkow HM, Wang E, et al. (2007) Transcriptional profiling of Alzheimer blood mononuclear cells by microarray. Neurobiology of Aging 28: 1795-1809.
13. Scherzer CR, Eklund AC, Morse LJ, Liao Z, Locascio JJ, et al. (2007) Molecular markers of early Parkinson's disease based on gene expression in blood. Proceedings of the National Academy of Sciences 104: 955-960.
14. Wu ZL, Ciallella JR, Flood DG, O'Kane TM, Bozyczko-Coyne D, et al. (2006) Comparative analysis of cortical gene expression in mouse models of Alzheimer's disease. Neurobiol Aging 27: 377-386.
15. Liu Z-P, Wang Y, Zhang X-S, Chen L, (2010) Identifying dysfunctional crosstalk of pathways in various regions of Alzheimer's disease brains. BMC Systems Biology 4: S2-S11.
16. del Sol A, Balling R, Hood L, Galas D, (2010) Diseases as network perturbations. Current Opinion in Biotechnology 21: 566-571.
17. Miller JA, Oldham MC, Geschwind DH, (2008) A Systems Level Analysis of Transcriptional Changes in Alzheimer's Disease and Normal Aging. Journal of Neuroscience 28: 1410-1420.
18. Ray M, Ruan J, Zhang W, (2008) Variations in the transcriptome of Alzheimer's disease reveal molecular networks involved in cardiovascular diseases. Genome Biology 9: R148.
19. Ray M, Zhang W, (2010) Analysis of Alzheimer's disease severity across brain regions by topological analysis of gene co-expression networks. BMC Systems Biology 4: 136.
20. Ideker T, Ozier O, Schwikowski B, Siegel AF, (2002) Discovering regulatory and signalling circuits in molecular interaction networks. Bioinformatics 18: S233-240.
21. Liu ZP, Wang Y, Zhang XS, Xia W, Chen L, (2011) Detecting and analyzing differentially activated pathways in brain regions of Alzheimer's disease patients. Mol Biosyst 7: 1441-1452.
22. Ideker T, Sharan R, (2008) Protein networks in disease. Genome Res 18: 644-652.
23. Sun J, Feng X, Liang D, Duan Y, Lei H, (2012) Down-Regulation of Energy Metabolism in Alzheimer's Disease is a Protective Response of Neurons to the Microenvironment. J Alzheimers Dis. 28: 389-402.
24. Dittrich MT, Klau GW, Rosenwald A, Dandekar T, Muller T, (2008) Identifying functional modules in protein-protein interaction networks: an integrated exact approach. Bioinformatics 24: i223-i231.
25. Jeong H, Mason SP, Barabasi AL, Oltvai ZN, (2001) Lethality and centrality in protein networks. Nature 411: 41-42.
26. Yu H, Greenbaum D, Xin Lu H, Zhu X, Gerstein M, (2004) Genomic analysis of essentiality within protein networks. Trends Genet 20: 227-231.
27. Casci T, (2006) Network fundamentals, via hub genes. Nature Reviews Genetics 7: 664-665.
28. Smyth GK, (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article3.
29. Pounds S, Morris SW, (2003) Estimating the occurrence of false positives and false negatives in microarray studies by approximating and partitioning the empirical distribution of p-values. Bioinformatics 19: 1236-1242.
30. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, et al. (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25: 25-29.
31. Docagne F, Gabriel C, Lebeurrier N, Lesne S, Hommet Y, et al. (2004) Sp1 and Smad transcription factors co-operate to mediate TGF-beta-dependent activation of amyloid-beta precursor protein gene transcription. Biochem J 383: 393-399.
32. Sun X, Wang Y, Qing H, Christensen MA, Liu Y, et al. (2005) Distinct transcriptional regulation and function of the human BACE2 and BACE1 genes. FASEB J 19: 739-749.
33. Heicklen-Klein A, Ginzburg I, (2000) Tau promoter confers neuronal specificity and binds Sp1 and AP-2. J Neurochem 75: 1408-1418.
34. Hamilton G, Proitsi P, Jehu L, Morgan A, Williams J, et al. (2007) Candidate gene association study of insulin signaling genes and Alzheimer's disease: Evidence for SOS2, PCK1, and PPAR gamma as susceptibility loci. American Journal of Medical Genetics Part B-Neuropsychiatric Genetics 144B: 508-516.
35. Nowak K, Lange-Dohna C, Zeitschel U, Gunther A, Luscher B, et al. (2006) The transcription factor Yin Yang 1 is an activator of BACE1 expression. Journal of Neurochemistry 96: 1696-1707.
36. Zambrano N, DeRenzis S, Minopoli G, Faraonio R, Donini V, et al. (1997) DNA-binding protein Pur alpha and transcription factor YY1 function as transcription activators of the neuron-specific FE65 gene promoter. Biochemical Journal 328: 293-300.
37. Sabo SL, Lanier LM, Ikin AF, Khorkova O, Sahasrabudhe S, et al. (1999) Regulation of beta-amyloid secretion by FE65, an amyloid protein precursor-binding protein. J Biol Chem 274: 7952-7957.
38. Jordan-Sciutto KL, Dragich JM, Caltagarone J, Hall DJ, Bowser R, (2000) Fetal Alz-50 clone 1 (FAC1) protein interacts with the Myc-associated zinc finger protein (ZF87/MAZ) and alters its transcriptional activity. Biochemistry 39: 3206-3215.
39. Giovanni A, Wirtz-Brugger F, Keramaris E, Slack R, Park DS, (1999) Involvement of cell cycle elements, cyclin-dependent kinases, pRb, and E2F x DP, in B-amyloid-induced neuronal death. J Biol Chem 274: 19011-19016.
40. Lee CS, Lee C, Hu T, Nguyen JM, Zhang JS, et al. (2011) Loss of nuclear factor E2-related factor 1 in the brain leads to dysregulation of proteasome gene expression and neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America 108: 8408-8413.
41. Tong L, Thornton PL, Balazs R, Cotman CW, (2001) Beta-amyloid-(1-42) impairs activity-dependent cAMP-response element-binding protein signaling in neurons at concentrations in which cell survival Is not compromised. J Biol Chem 276: 17301-17306.
42. Manolopoulos KN, Klotz LO, Korsten P, Bornstein SR, Barthel A, (2010) Linking Alzheimer's disease to insulin resistance: the FoxO response to oxidative stress. Mol Psychiatry 15: 1046-1052.
43. Salins P, Shawesh S, He Y, Dibrov A, Kashour T, et al. (2007) Lovastatin protects human neurons against Abeta-induced toxicity and causes activation of beta-catenin-TCF/LEF signaling. Neurosci Lett 412: 211-216.
44. Yamamoto Y, Gaynor RB, (2004) I kappa B kinases: key regulators of the NF-kappa B pathway. Trends in Biochemical Sciences 29: 72-79.
45. Tsujio I, Tanaka T, Kudo T, Nishikawa T, Shinozaki K, et al. (2000) Inactivation of glycogen synthase kinase-3 by protein kinase C delta: implications for regulation of tau phosphorylation. FEBS Lett 469: 111-117.
46. Crary JF, Shao CY, Mirra SS, Hernandez AI, Sacktor TC, (2006) Atypical protein kinase C in neurodegenerative disease I: PKMzeta aggregates with limbic neurofibrillary tangles and AMPA receptors in Alzheimer disease. J Neuropathol Exp Neurol 65: 319-326.
47. Kaytor MD, Orr HT, (2002) The GSK3 beta signaling cascade and neurodegenerative disease. Curr Opin Neurobiol 12: 275-278.
48. Zhu X, Lee HG, Raina AK, Perry G, Smith MA, (2002) The role of mitogen-activated protein kinase pathways in Alzheimer's disease. Neurosignals 11: 270-281.
49. Trinczek B, Brajenovic M, Ebneth A, Drewes G, (2004) MARK4 is a novel microtubule-associated proteins/microtubule affinity-regulating kinase that binds to the cellular microtubule network and to centrosomes. Journal of Biological Chemistry 279: 5915-5923.
50. Cruz JC, Tsai LH, (2004) Cdk5 deregulation in the pathogenesis of Alzheimer's disease. Trends Mol Med 10: 452-458.
51. Mei M, Su B, Harrison K, Chao M, Siedlak SL, et al. (2006) Distribution, levels and phosphorylation of Raf-1 in Alzheimer's disease. J Neurochem 99: 1377-1388.
52. Figgins JA, Minster RL, Demirci FY, Dekosky ST, Kamboh MI, (2009) Association studies of 22 candidate SNPs with late-onset Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 150B: 520-526.
53. Grupe A, Abraham R, Li Y, Rowland C, Hollingworth P, et al. (2007) Evidence for novel susceptibility genes for late-onset Alzheimer's disease from a genome-wide association study of putative functional variants. Hum Mol Genet 16: 865-873.
54. Giedraitis V, Kilander L, Degerman-Gunnarsson M, Sundelof J, Axelsson T, et al. (2009) Genetic analysis of Alzheimer's disease in the Uppsala Longitudinal Study of Adult Men. Dement Geriatr Cogn Disord 27: 59-68.
55. Li H, Wetten S, Li L, St Jean PL, Upmanyu R, et al. (2008) Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol 65: 45-53.
56. Reiman EM, Webster JA, Myers AJ, Hardy J, Dunckley T, et al. (2007) GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron 54: 713-720.
57. Engidawork E, Gulesserian T, Yoo BC, Cairns N, Lubec G, (2001) Alteration of caspases and apoptosis-related proteins in brains of patients with Alzheimer's disease. Biochem Biophys Res Commun 281: 84-93.
58. Webster JA, Gibbs JR, Clarke J, Ray M, Zhang W, et al. (2009) Genetic Control of Human Brain Transcript Expression in Alzheimer Disease. The American Journal of Human Genetics 84: 445-458.
59. Liao L, Cheng D, Wang J, Duong DM, Losik TG, et al. (2004) Proteomic characterization of postmortem amyloid plaques isolated by laser capture microdissection. J Biol Chem 279: 37061-37068.
60. Wang Q, Woltjer RL, Cimino PJ, Pan C, Montine KS, et al. (2005) Proteomic analysis of neurofibrillary tangles in Alzheimer disease identifies GAPDH as a detergent-insoluble paired helical filament tau binding protein. FASEB J 19: 869-871.
61. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE, (2007) Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 39: 17-23.
62. de Magalhaes JP, Toussaint O, (2004) GenAge: a genomic and proteomic network map of human ageing. FEBS Lett 571: 243-247.
63. de Magalhaes JP, Budovsky A, Lehmann G, Costa J, Li Y, et al. (2009) The Human Ageing Genomic Resources: online databases and tools for biogerontologists. Aging Cell 8: 65-72.
64. Maes OC, Xu S, Yu B, Chertkow HM, Wang E, et al. (2007) Transcriptional profiling of Alzheimer blood mononuclear cells by microarray. Neurobiol Aging 28: 1795-1809.
65. Scherzer CR, Eklund AC, Morse LJ, Liao Z, Locascio JJ, et al. (2007) Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci U S A 104: 955-960.
66. Chen KD, Chang PT, Ping YH, Lee HC, Yeh CW, et al. (2011) Gene expression profiling of peripheral blood leukocytes identifies and validates ABCB1 as a novel biomarker for Alzheimer's disease. Neurobiology of Disease 43: 698-705.
67. Fehlbaum-Beurdeley P, Jarrige-Le Prado AC, Pallares D, Carriere J, Guihal C, et al. (2010) Toward an Alzheimer's disease diagnosis via high-resolution blood gene expression. Alzheimers Dement 6: 25-38.
68. Hopkins AL, (2007) Network pharmacology. Nat Biotechnol 25: 1110-1111.
69. Hopkins AL, (2008) Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 4: 682-690.
70. Spilman P, Podlutskaya N, Hart MJ, Debnath J, Gorostiza O, et al. (2010) Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PLoS ONE 5: e9979.
71. Meske V, Albert F, Ohm TG, (2008) Coupling of mammalian target of rapamycin with phosphoinositide 3-kinase signaling pathway regulates protein phosphatase 2A- and glycogen synthase kinase-3-dependent phosphorylation of Tau. J Biol Chem 283: 100-109.
72. Pei JJ, Hugon J, (2008) mTOR-dependent signalling in Alzheimer's disease. J Cell Mol Med 12: 2525-2532.
73. Cole GM, Teter B, Frautschy SA, (2007) Neuroprotective effects of curcumin. Adv Exp Med Biol 595: 197-212.
74. Kato K, Ito H, Kamei K, Iwamoto I, (1998) Stimulation of the stress-induced expression of stress proteins by curcumin in cultured cells and in rat tissues in vivo. Cell Stress Chaperones 3: 152-160.
75. Cardinaux JR, Allaman I, Magistretti PJ, (2000) Pro-inflammatory cytokines induce the transcription factors C/EBPbeta and C/EBPdelta in astrocytes. Glia 29: 91-97.
76. Ejarque-Ortiz A, Medina MG, Tusell JM, Perez-Gonzalez AP, Serratosa J, et al. (2007) Upregulation of CCAAT/enhancer binding protein beta in activated astrocytes and microglia. Glia 55: 178-188.
77. Perez-Capote K, Saura J, Serratosa J, Sola C, (2006) Expression of C/EBPalpha and C/EBPbeta in glial cells in vitro after inducing glial activation by different stimuli. Neurosci Lett 410: 25-30.
78. Kitamura Y, Shimohama S, Ota T, Matsuoka Y, Nomura Y, et al. (1997) Alteration of transcription factors NF-kappaB and STAT1 in Alzheimer's disease brains. Neurosci Lett 237: 17-20.
79. Pan R, Qiu S, Lu DX, Dong J, (2008) Curcumin improves learning and memory ability and its neuroprotective mechanism in mice. Chin Med J (Engl) 121: 832-839.
80. Rolfe DF, Brown GC, (1997) Cellular energy utilization and molecular origin of standard metabolic rate in mammals. Physiol Rev 77: 731-758.
81. Hastings ML, Allemand E, Duelli DM, Myers MP, Krainer AR, (2007) Control of pre-mRNA splicing by the general splicing factors PUF60 and U2AF(65). PLoS ONE 2: e538.
82. Eschbach J, Dupuis L, (2011) Cytoplasmic dynein in neurodegeneration. Pharmacol Ther 130: 348-363.
83. Jensen PH, Hager H, Nielsen MS, Hojrup P, Gliemann J, et al. (1999) alpha-synuclein binds to Tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356. J Biol Chem 274: 25481-25489.
84. Fletcher AI, Shuang R, Giovannucci DR, Zhang L, Bittner MA, et al. (1999) Regulation of exocytosis by cyclin-dependent kinase 5 via phosphorylation of Munc18. J Biol Chem 274: 4027-4035.
85. Min MY, Yang HW, Yen CT, Chen CC, Cheng SJ, (2011) ERK, synaptic plasticity and acid-induced muscle pain. Commun Integr Biol 4: 394-396.
86. Cohen-Matsliah SI, Seroussi Y, Rosenblum K, Barkai E, (2008) Persistent ERK activation maintains learning-induced long-lasting modulation of synaptic connectivity. Learn Mem 15: 756-761.
87. Tsugu Y, Ojika K, Matsukawa N, Iwase T, Otsuka Y, et al. (1998) High levels of hippocampal cholinergic neurostimulating peptide (HCNP) in the CSF of some patients with Alzheimer's disease. European Journal of Neurology 5: 561-569.
88. Leuba G, Savioz A, Vernay A, Carnal B, Kraftsik R, et al. (2008) Differential changes in synaptic proteins in the Alzheimer frontal cortex with marked increase in PSD-95 postsynaptic protein. J Alzheimers Dis 15: 139-151.
89. Tezuka T, Umemori H, Akiyama T, Nakanishi S, Yamamoto T, (1999) PSD-95 promotes Fyn-mediated tyrosine phosphorylation of the N-methyl-D-aspartate receptor subunit NR2A. Proc Natl Acad Sci U S A 96: 435-440.
90. Hou XY, Zhang GY, Yan JZ, Chen M, Liu Y, (2002) Activation of NMDA receptors and L-type voltage-gated calcium channels mediates enhanced formation of Fyn-PSD95-NR2A complex after transient brain ischemia. Brain Res 955: 123-132.
91. Gerber U, Gee CE, Benquet P, (2007) Metabotropic glutamate receptors: intracellular signaling pathways. Curr Opin Pharmacol 7: 56-61.
92. Davidson JD, Riley B, Burright EN, Duvick LA, Zoghbi HY, et al. (2000) Identification and characterization of an ataxin-1-interacting protein: A1Up, a ubiquitin-like nuclear protein. Hum Mol Genet 9: 2305-2312.
93. Gamerdinger M, Hajieva P, Kaya AM, Wolfrum U, Hartl FU, et al. (2009) Protein quality control during aging involves recruitment of the macroautophagy pathway by BAG3. EMBO J 28: 889-901.
94. Ding WX, Yin XM, (2008) Sorting, recognition and activation of the misfolded protein degradation pathways through macroautophagy and the proteasome. Autophagy 4: 141-150.
95. Bence NF, Sampat RM, Kopito RR, (2001) Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292: 1552-1555.
96. Caltagarone J, Jing Z, Bowser R, (2007) Focal adhesions regulate Abeta signaling and cell death in Alzheimer's disease. Biochim Biophys Acta 1772: 438-445.
97. Cozza A, Melissari E, Iacopetti P, Mariotti V, Tedde A, et al. (2008) SNPs in neurotrophin system genes and Alzheimer's disease in an Italian population. J Alzheimers Dis 15: 61-70.
98. Matsui T, Ramasamy K, Ingelsson M, Fukumoto H, Conrad C, et al. (2006) Coordinated expression of caspase 8, 3 and 7 mRNA in temporal cortex of Alzheimer disease: relationship to formic acid extractable abeta42 levels. J Neuropathol Exp Neurol 65: 508-515.
99. Zhang Y, Goodyer C, LeBlanc A, (2000) Selective and protracted apoptosis in human primary neurons microinjected with active caspase-3,-6,-7, and-8. J Neurosci 20: 8384-8389.
100. Katsoulidis E, Li Y, Mears H, Platanias LC, (2005) The p38 mitogen-activated protein kinase pathway in interferon signal transduction. J Interferon Cytokine Res 25: 749-756.
101. Viatour P, Merville MP, Bours V, Chariot A, (2005) Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation. Trends in Biochemical Sciences 30: 43-52.
102. Liang WS, Dunckley T, Beach TG, Grover A, Mastroeni D, et al. (2007) Gene expression profiles in anatomically and functionally distinct regions of the normal aged human brain. Physiol Genomics 28: 311-322.
103. Fischer A, Sananbenesi F, Mungenast A, Tsai LH, (2010) Targeting the correct HDAC(s) to treat cognitive disorders. Trends Pharmacol Sci 31: 605-617.
104. Wood MA, Attner MA, Oliveira AMM, Brindle PK, Abel T, (2006) A transcription factor-binding domain of the coactivator CBP is essential for long-term memory and the expression of specific target genes. Learning & Memory 13: 609-617.
105. Wood MA, Kaplan MP, Park A, Blanchard EJ, Oliveira AM, et al. (2005) Transgenic mice expressing a truncated form of CREB-binding protein (CBP) exhibit deficits in hippocampal synaptic plasticity and memory storage. Learn Mem 12: 111-119.
106. Oliveira AM, Wood MA, McDonough CB, Abel T, (2007) Transgenic mice expressing an inhibitory truncated form of p300 exhibit long-term memory deficits. Learn Mem 14: 564-572.
107. Maurice T, Duclot F, Meunier J, Naert G, Givalois L, et al. (2008) Altered memory capacities and response to stress in p300/CBP-associated factor (PCAF) histone acetylase knockout mice. Neuropsychopharmacology 33: 1584-1602.
108. Bousiges O, de Vasconcelos AP, Neidl R, Cosquer B, Herbeaux K, et al. (2010) Spatial Memory Consolidation is Associated with Induction of Several Lysine-Acetyltransferase (Histone Acetyltransferase) Expression Levels and H2B/H4 Acetylation-Dependent Transcriptional Events in the Rat Hippocampus. Neuropsychopharmacology 35: 2521-2537.
109. Kim D, Frank CL, Dobbin MM, Tsunemoto RK, Tu W, et al. (2008) Deregulation of HDAC1 by p25/Cdk5 in neurotoxicity. Neuron 60: 803-817.
110. Zhang Y, Champagne N, Beitel LK, Goodyer CG, Trifiro M, et al. (2004) Estrogen and androgen protection of human neurons against intracellular amyloid beta1-42 toxicity through heat shock protein 70. J Neurosci 24: 5315-5321.
111. McEwen BS, De Kloet ER, Rostene W, (1986) Adrenal steroid receptors and actions in the nervous system. Physiol Rev 66: 1121-1188.
112. Seckl JR, Dickson KL, Yates C, Fink G, (1991) Distribution of glucocorticoid and mineralocorticoid receptor messenger RNA expression in human postmortem hippocampus. Brain Res 561: 332-337.
113. de Quervain DJ, Roozendaal B, McGaugh JL, (1998) Stress and glucocorticoids impair retrieval of long-term spatial memory. Nature 394: 787-790.
114. Roozendaal B, (2000) 1999 Curt P. Richter award. Glucocorticoids and the regulation of memory consolidation. Psychoneuroendocrinology 25: 213-238.
115. Berchtold NC, Cribbs DH, Coleman PD, Rogers J, Head E, et al. (2008) Gene expression changes in the course of normal brain aging are sexually dimorphic. Proc Natl Acad Sci U S A 105: 15605-15610.
116. Bossers K, Wirz KTS, Meerhoff GF, Essing AHW, van Dongen JW, et al. (2010) Concerted changes in transcripts in the prefrontal cortex precede neuropathology in Alzheimer's disease. Brain 133: 3699-3723.
117. Murayama KS, Kametani F, Saito S, Kume H, Akiyama H, et al. (2006) Reticulons RTN3 and RTN4-B/C interact with BACE1 and inhibit its ability to produce amyloid beta-protein. Eur J Neurosci 24: 1237-1244.
118. Zhang C, Browne A, Child D, Divito JR, Stevenson JA, et al. (2010) Loss of function of ATXN1 increases amyloid beta-protein levels by potentiating beta-secretase processing of beta-amyloid precursor protein. J Biol Chem 285: 8515-8526.
119. Wang L, Shim H, Xie C, Cai H, (2008) Activation of protein kinase C modulates BACE1-mediated beta-secretase activity. Neurobiol Aging 29: 357-367.
120. Buxbaum JD, Gandy SE, Cicchetti P, Ehrlich ME, Czernik AJ, et al. (1990) Processing of Alzheimer beta/A4 amyloid precursor protein: modulation by agents that regulate protein phosphorylation. Proc Natl Acad Sci U S A 87: 6003-6006.
121. Wen Y, Yu WH, Maloney B, Bailey J, Ma J, et al. (2008) Transcriptional regulation of beta-secretase by p25/cdk5 leads to enhanced amyloidogenic processing. Neuron 57: 680-690.
122. Anderson AJ, Cummings BJ, Cotman CW, (1994) Increased Immunoreactivity for Jun-Related and Fos-Related Proteins in Alzheimers-Disease- Association with Pathology. Experimental Neurology 125: 286-295.
123. Pearson AG, Byrne UTE, MacGibbon GA, Faull RLM, Dragunow M, (2006) Activated c-Jun is present in neurofibrillary tangles in Alzheimer's disease brains. Neuroscience Letters 398: 246-250.
124. Ferrer I, Segui J, Planas AM, (1996) Amyloid deposition is associated with c-Jun expression in Alzheimer's disease and amyloid angiopathy. Neuropathology and Applied Neurobiology 22: 521-526.
125. Layfield R, Fergusson J, Aitken A, Lowe J, Landon M, et al. (1996) Neurofibrillary tangles of Alzheimer's disease brains contain 14-3-3 proteins. Neurosci Lett 209: 57-60.
126. Mateo I, Llorca J, Infante J, Rodriguez-Rodriguez E, Berciano J, et al. (2008) Gene-gene interaction between 14-3-3 zeta and butyrylcholinesterase modulates Alzheimer's disease risk. European Journal of Neurology 15: 219-222.
127. Mateo I, Sanchez-Juan P, Rodriguez-Rodriguez E, Infante J, Fernandez-Viadero C, et al. (2008) 14-3-3 zeta and tau genes interactively decrease Alzheimer's disease risk. Dement Geriatr Cogn Disord 25: 317-320.
128. Li T, Paudel HK, (2007) 14-3-3 zeta Facilitates GSK3 beta-catalyzed tau phosphorylation in HEK-293 cells by a mechanism that requires phosphorylation of GSK3 beta on Ser(9). Neuroscience Letters 414: 203-208.
129. Sugimori K, Kobayashi K, Kitamura T, Sudo S, Koshino Y, (2007) 14-3-3 protein beta isoform is associated with 3-repeat tau neurofibrillary tangles in Alzheimer's disease. Psychiatry and Clinical Neurosciences 61: 159-167.
130. Chun J, Kwon T, Lee EJ, Kim CH, Han YS, et al. (2004) 14-3-3 Protein mediates phosphorylation of microtubule-associated protein tau by serum- and glucocorticoid-induced protein kinase 1. Mol Cells 18: 360-368.
131. Aksenova MV, Burbaeva GS, Kandror KV, Kapkov DV, Stepanov AS, (1991) The decreased level of casein kinase 2 in brain cortex of schizophrenic and Alzheimer's disease patients. FEBS Lett 279: 55-57.
132. Lebouvier T, Scales TME, Hanger DP, Geahlen RL, Lardeux B, et al. (2008) The microtubule-associated protein tau is phosphorylated by Syk. Biochimica Et Biophysica Acta-Molecular Cell Research 1783: 188-192.
133. Wilmot B, McWeeney SK, Nixon RR, Montine TJ, Laut J, et al. (2008) Translational gene mapping of cognitive decline. Neurobiol Aging 29: 524-541.
134. Ray M, Ruan J, Zhang W, (2008) Variations in the transcriptome of Alzheimer's disease reveal molecular networks involved in cardiovascular diseases. Genome Biol 9: R148.
135. Keshava Prasad TS, Goel R, Kandasamy K, Keerthikumar S, Kumar S, et al. (2009) Human Protein Reference Database-2009 update. Nucleic Acids Res 37: D767-772.
136. Beisser D, Klau GW, Dandekar T, Muller T, Dittrich MT, (2010) BioNet: an R-Package for the functional analysis of biological networks. Bioinformatics 26: 1129-1130.
137. Huang DW, Sherman BT, Lempicki RA, (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature Protocols 4: 44-57.
138. Duncan D, Prodduturi N, Zhang B, (2010) WebGestalt2: an updated and expanded version of the Web-based Gene Set Analysis Toolkit. BMC Bioinformatics 11: S4-P10.
139. Lachmann A, Ma'ayan A, (2009) KEA: kinase enrichment analysis. Bioinformatics 25: 684-686.
140. Chen J, Bardes EE, Aronow BJ, Jegga AG, (2009) ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res 37: W305-311.
141. Merico D, Isserlin R, Stueker O, Emili A, Bader GD, (2010) Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS ONE 5: e13984.
142. Zhang Y, James M, Middleton FA, Davis RL, (2005) Transcriptional analysis of multiple brain regions in Parkinson's disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms. Am J Med Genet B Neuropsychiatr Genet 137B: 5-16.
143. Lesnick TG, Papapetropoulos S, Mash DC, Ffrench-Mullen J, Shehadeh L, et al. (2007) A genomic pathway approach to a complex disease: axon guidance and Parkinson disease. PLoS Genet 3: e98.
144. Hodges A, Strand AD, Aragaki AK, Kuhn A, Sengstag T, et al. (2006) Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet 15: 965-977.
145. Iwamoto K, Kakiuchi C, Bundo M, Ikeda K, Kato T, (2004) Molecular characterization of bipolar disorder by comparing gene expression profiles of postmortem brains of major mental disorders. Mol Psychiatry 9: 406-416.
146. Maycox PR, Kelly F, Taylor A, Bates S, Reid J, et al. (2009) Analysis of gene expression in two large schizophrenia cohorts identifies multiple changes associated with nerve terminal function. Mol Psychiatry 14: 1083-1094.
147. Webster JA, Gibbs JR, Clarke J, Ray M, Zhang W, et al. (2009) Genetic control of human brain transcript expression in Alzheimer disease. Am J Hum Genet 84: 445-458.
148. Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, et al. (2004) Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci U S A 101: 2173-2178.